Focus on the controversial activation of human iNKT cells by 4-deoxy analogue of KRN7000

Journal of Medicinal Chemistry

Volumn 52, Issue 15, 2009, Pages 4960-4963

  Lacône, Vivien ^a,b   Hunault, Julie ^a   Pipelier, Muriel ^a   Blot, Virginie ^a   Lecourt, Thomas ^b   Rocher, Jézabelle ^a   Turcot Dubois, Anne Laure ^a   Marionneau, Séverine ^c   Douillard, Jean Yves ^c   Clément, Monique ^a   Le Pendu, Jacques ^a   Bonneville, Marc ^a   Micouin, Laurent ^b   Dubreuil, Didier ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; 4 DEOXY ALPHA GALACTOSYLCERAMIDE DERIVATIVE; GALACTOSIDE; GALACTOSYLCERAMIDE; INTERLEUKIN 4; SPHINGOSINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN;

EID: 68549122713     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900290r     Document Type: Article

References (20)

1. (a) Bendelac, A.; Savage, P. B.; Teyton, L. The biology of NKT cells. Annu. Rev. Immunol. 2007, 25, 297-336.
2. Yu, K. O. A.; Porcelli, S. A. The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy. Immunol. Lett. 2005, 100, 42-55.
3. Moody, D. B. How a T cell sees sugar. Nature 2007, 448, 36-37.
4. Natori, T.; Morita, M.; Akimoto, K.; Koezuka, Y. Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas Mauritianus. Tetrahedron 1994, 50, 2771-2784.
5. (a) Mattner, J.; DeBord, K. L.; Ismail, N.; Goff, R. D.; Cantu, C. III; Zhou, D.; Saint-Mezard, P.; Wang, V.; Gao, Y.; Yin, N.; Hoebe, K.; Schneewind, O.; Walker, D.; Beutler, B.; Teyton, L.; Savage, P. B.; Bendelac, A. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005, 434, 525-529.
6. (b) Zhou, D. P.; Mattner, J.; Cantu, C.; Schrantz, N.; Yin, N.; Gao, Y.; Sagiv, Y.; Hudspeth, K.;Wu, Y. P.; Yamashita, T.; Teneberg, S.; Wang, D. C.; Proia, R. L.; Levery, S. B.; Savage, P. B.; Teyton, L.; Bendelac, A. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004, 306, 1786-1789.
7. Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; Yamaji, K.; Koezuka, Y.; Kobayashi, E.; Fukushima, H. Structure-activity relationship of α-galatosylceramides against B16-bearing mice. J. Med. Chem. 1995, 38, 2176-2187.
8. (a) Savage, P. B.; Teyton, L.; Bendelac, A. Glycolipids for natural killer T cells. Chem. Soc. Rev. 2006, 35, 771-779.
9. (b) Wu, D.; Fujio, M.; Wong, C.-H. Glycolipids as immunostimulating agents. Bioorg. Med. Chem. 2008, 16, 1073-1083.
10. Brossay, L.; Naidenko, O.; Burdin, N.; Matsuda, J.; Sakia, T.; Kronenberg, M. Cutting edge: structural requirements for galactosylceramide recognition by CD1-restricted NK T cells. J. Immunol. 1998, 161, 5124-5128.
11. Sidobre, S.; Hammond, K. J. L.; Benazet-Sidobre, L.; Maltsev, S. D.; Richardson, S. K.; Ndonye, R. M.; Howell, A. R.; Sakai, T.; Besra, G. S.; Porcelli, S. A.; Kronenberg, M. The T cell antigen receptor expressed by V alpha 14i NKT cells has a unique mode of glycosphingolipid antigen recogniton. Proc. Natl. Acad. Sci. U.S. A. 2004, 101, 12254-12259.
12. Borg, N. A.; Wun, K. S.; Kjer-Nielsen, L.; Wilce, M. C. J.; Pellici, D. G.; Koh, R.; Besra, G. S.; Bharadwaj, M.; Godfrey, D. I.; McCluskey, J.; Rossjohn, J. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007, 448, 44-49.
13. Godfrey, D. I.; McCluskey, J.; Rossjohn, J. CD1d antigen presentation: treats for NKT cells. Nat. Immunol. 2005, 6, 754-756.
14. Ndonye, R. M.; Izmirian, D. P.; Dunn, M. F.; Yu, K. O. A.; Porcelli, S. A.; Khurana, A.; Kronenberg, M.; Richardson, S. K.; Howell, A. R. Synthesis and evaluation of sphinganine analogues of KRN7000 and OCH. J. Org. Chem. 2005, 70, 10260-10270.
15. Dubreuil, D.; Pipelier, M.; Micouin, L.; Lacône, V.; Bonneville, M.; Le Pendu, J. α-Galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods and pharmaceutical compositions containing them. Patent PCT/ IB2007/004270, 2007; PCT/IB2006/0039292006.
16. See Supporting Information for references on the synthesis of sphinganine fragments from chiral pool.
17. (a) Vo-hoang, Y.; Micouin, L.; Ronet, C.; Gachelin, G.; Bonin, M. Total enantioselective synthesis and in vivo biological evaluation of a novel fluorescent BODIPY α-galactosylceramide. ChemBioChem 2003, 4, 27-33.
18. (b) Cai, Y.; Ling, C.-C.; Bundle, D. R. A general, efficient and stereospecific route to sphingosine, sphinganines, phytosphingosines and their analogs. Org. Biomol. Chem. 2006, 4, 1140-1146.
19. Mukaiyama, T.; Murai, Y.; Shoda, S. An efficient method for glucosylation oh hydroxy compounds using glucopyranosyl fluoride. Chem. Lett. 1981, 431-432.
20. Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands. Org. Lett. 1999, 1, 953-956.